Insider Trading Alert - Cimarex Energy Company And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 26, 2013, 73 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.03 to $367,425,000.00.

Highlighted Stocks Traded by Insiders:

Cimarex Energy Company (XEC) - FREE Research Report

Bell Stephen P who is Ex VP at Cimarex Energy Company sold 4,468 shares at $94.91 on Sept. 26, 2013. Following this transaction, the Ex VP owned 80,393 shares meaning that the stake was reduced by 5.27% with the 4,468 share transaction.

Albi Joseph R who is Executive VP, COO at Cimarex Energy Company sold 2,000 shares at $95.48 on Sept. 26, 2013. Following this transaction, the Executive VP, COO owned 68,886 shares meaning that the stake was reduced by 2.82% with the 2,000 share transaction.

The shares most recently traded at $95.79, up $0.31, or 0.33% since the insider transaction. Historical insider transactions for Cimarex Energy Company go as follows:

  • 4-Week # shares sold: 16,747
  • 12-Week # shares sold: 39,513
  • 24-Week # shares sold: 39,513

The average volume for Cimarex Energy Company has been 790,000 shares per day over the past 30 days. Cimarex Energy Company has a market cap of $8.1 billion and is part of the basic materials sector and energy industry. Shares are up 62.62% year to date as of the close of trading on Wednesday.

Cimarex Energy Co. operates as an independent oil and gas exploration and production company primarily in Oklahoma, Texas, New Mexico, and Kansas. As of December 31, 2012, the company owned an interest in 4,953 net productive oil and gas wells. The stock currently has a dividend yield of 0.6%. The company has a P/E ratio of 20.3. Currently there are 11 analysts that rate Cimarex Energy Company a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XEC - FREE

TheStreet Quant Ratings rates Cimarex Energy Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, increase in net income, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Cimarex Energy Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Stryker Corporation (SYK) - FREE Research Report

Stryker Ronda E who is Director at Stryker Corporation sold 14,000 shares at $68.80 on Sept. 26, 2013. Following this transaction, the Director owned 11.7 million shares meaning that the stake was reduced by 0.12% with the 14,000 share transaction.

The shares most recently traded at $68.40, down $0.40, or 0.58% since the insider transaction. Historical insider transactions for Stryker Corporation go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 28,000

The average volume for Stryker Corporation has been 1.2 million shares per day over the past 30 days. Stryker Corporation has a market cap of $26.8 billion and is part of the health care sector and health services industry. Shares are up 29.2% year to date as of the close of trading on Wednesday.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. The stock currently has a dividend yield of 1.5%. The company has a P/E ratio of 23.8. Currently there are 13 analysts that rate Stryker Corporation a buy, 1 analyst rates it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYK - FREE

TheStreet Quant Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Cepheid (CPHD) - FREE Research Report

Gutshall Thomas L who is Director at Cepheid sold 3,000 shares at $38.97 on Sept. 26, 2013. Following this transaction, the Director owned 382,800 shares meaning that the stake was reduced by 0.78% with the 3,000 share transaction.

The shares most recently traded at $39.25, up $0.28, or 0.71% since the insider transaction. Historical insider transactions for Cepheid go as follows:

  • 4-Week # shares sold: 5,129
  • 12-Week # shares sold: 5,289
  • 24-Week # shares sold: 18,339

The average volume for Cepheid has been 449,700 shares per day over the past 30 days. Cepheid has a market cap of $2.6 billion and is part of the technology sector and electronics industry. Shares are up 15.59% year to date as of the close of trading on Wednesday.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market. Currently there are 12 analysts that rate Cepheid a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPHD - FREE

TheStreet Quant Ratings rates Cepheid as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Cepheid Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Splunk (SPLK) - FREE Research Report

Neustaetter Thomas M who is Director at Splunk sold 1,500 shares at $60.50 on Sept. 26, 2013. Following this transaction, the Director owned 97,103 shares meaning that the stake was reduced by 1.52% with the 1,500 share transaction.

The shares most recently traded at $61.97, up $1.47, or 2.38% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 241,613
  • 12-Week # shares sold: 335,053
  • 24-Week # shares sold: 370,524

The average volume for Splunk has been 1.1 million shares per day over the past 30 days. Splunk has a market cap of $6.4 billion and is part of the technology sector and computer software & services industry. Shares are up 108.03% year to date as of the close of trading on Wednesday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence. Currently there are 11 analysts that rate Splunk a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Chicago Bridge & Iron Company (CBI) - FREE Research Report

Mullen Patrick K who is Executive Vice President at Chicago Bridge & Iron Company sold 4,500 shares at $67.00 on Sept. 26, 2013. Following this transaction, the Executive Vice President owned 20,999 shares meaning that the stake was reduced by 17.65% with the 4,500 share transaction.

The shares most recently traded at $67.09, up $0.09, or 0.13% since the insider transaction. Historical insider transactions for Chicago Bridge & Iron Company go as follows:

  • 4-Week # shares sold: 125,109
  • 12-Week # shares sold: 135,109
  • 24-Week # shares sold: 348,606

The average volume for Chicago Bridge & Iron Company has been 982,100 shares per day over the past 30 days. Chicago Bridge & Iron Company has a market cap of $7.1 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 43.17% year to date as of the close of trading on Wednesday.

Chicago Bridge & Iron Company N.V., an energy infrastructure focused company, provides conceptual design, technology, engineering, procurement, fabrication, construction, and commissioning services to customers in the energy, petrochemical, and natural resource industries worldwide. The stock currently has a dividend yield of 0.3%. The company has a P/E ratio of 21.8. Currently there are 10 analysts that rate Chicago Bridge & Iron Company a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBI - FREE

TheStreet Quant Ratings rates Chicago Bridge & Iron Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, growth in earnings per share, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Chicago Bridge & Iron Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null